King's College London

The King’s Spinout Accelerator is a 12-month programme, transforming early-stage prospective spinouts into robust commercial propositions. Over the next 12 months, the prospective spinouts will access interactive masterclasses led by experts, skill development sessions to explore commercial pathways for impact, implement evidence-based validation and explore partnership opportunities, coaching, a peer network, desk space and King’s Investor Network.

The eight spinouts on Cohort II span seven of King’s nine faculties. The biggest growth comes from the Faculty of Natural, Mathematical & Engineering Sciences, up to 25% this year. For the first time, there is representation from the Dickson Poon School of Law. 38% of the ventures are women-led, demonstrating our commitment to gender diversity in entrepreneurship.

King’s has a long history of successful technology transfer and commercialisation of research discoveries. The King’s Spinout Accelerator is delivered in partnership with King’s Innovation Catalyst, drawing together expertise from Translational Research Support, IP & Licensing and Industry Partnerships, to facilitate the creation of knowledge exchange, ventures and intellectual property.

Several of the ventures in last year’s first Spinout Accelerator cohort have raised, or are actively raising investment and are progressing through the spinout process. One of the ventures PharosAI received £18.9 million in funding from the UK Government to democratise cancer AI research and accelerate the path to cancer care.

This year’s cohort are advancing innovations in health, tech and security.

 

Meet the prospective spinouts

ChemKAS Pharmaceutics

Developing radiopharmaceuticals.

Academic/research lead: Stephen Archibald and Abid Khan, Faculty of Life Sciences & Medicine.

 

HeadNote.AI

Headnote Harvester.

Academic/research lead: Dr Niccolò Ridi, Dickson Poon School of Law.

 

Improving Supply Chain Risk Management

Reducing counterfeiting risks in critical industries.

Academic/research lead: Professor Christopher Hobbs, Faculty of Social Science & Public Policy.

 

MetaSenZ

Ultrasensitive gas sensors for safe hydrogen detection in a green energy future.

Academic/research lead: Dr Anastasiia Zaleska and Professor Anatoly Zayats, Faculty of Natural, Mathematical & Engineering Sciences.

 

NeuroPrognostix

A neurogenesis-based blood test to transform early diagnosis and treatment monitoring across neurological and psychiatric disorders.

Academic/research lead: Dr Sandrine Thuret and Dr Edina Silajdzic, Institute of Psychiatry, Psychology & Neuroscience.

 

Opis

Leveraging cutting-edge AI and patient retention research to deliver accurate, low-burden food intake monitoring for clinical trials. 

Academic/research lead: Professor Gerome Breen and Ivan Andrushevich Petukhov, Institute of Psychiatry, Psychology & Neuroscience.

 

Precise Therapeutics

Next generation of therapies to prevent fibrosis in the eye and blindness.

Academic/research lead: Dr Cynthia Yu Wai Man, Faculty of Life Sciences & Medicine.

 

X-Mark

AI-driven assessment platform providing explainable grading and personalised feedback for short essay questions to empower schools and examination boards.

Academic/research lead: Professor Yulan He, Dr Runcong Zhao and Jiazheng Li, Faculty of Natural, Mathematical & Engineering Sciences.

 

If you are an investor, with an active interest in early-stage spinouts, please contact our Investor Relations Manager, Dr Yotam Levy, or sign-up to our monthly investor newsletter.